1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

FDA OK's BI's Gilotrif in NSCLC, with Qiagen's therascreen Dx

 
• By Donna Young

Patients with metastatic non-small cell lung cancer (NSCLC) with certain epidermal growth factor receptor (EGFR) mutations have a new treatment option after the FDA's 12 July approval of Boehringer Ingelheim's new drug application (NDA) to market Gilotrif (afatinib).

Patients with metastatic non-small cell lung cancer (NSCLC) with certain epidermal growth factor receptor (EGFR) mutations have a new treatment option after the FDA's 12 July approval of Boehringer Ingelheim's new drug application (NDA) to market Gilotrif (afatinib).

The agency also gave its OK to Qiagen for its companion diagnostic test, therascreen EGFR RGQ PCR Kit, which is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.